GM-CSF (granulocyte/macrophage colony-stimulating factor) was found to be highly protective in pre-clinical models of pneumonia-associated lung injury including viral infection. There is first evidence of a beneficial effect of inhaled GM-CSF in patients with severe pneumonia/ARDS. A placebo-controlled, randomized clinical phase II investigator-initiated trial (GI-HOPE, NCT02595060) currently addresses the adjunctive therapeutic role of aerosolized GM-CSF in patients with pneumonia-related ARDS (for further details see project 9). The study was extended to COVID-19 patients, please find the BMBF report here.
Progress Reports 2020
ECCPS Seminar Room
Feb, 7th 13:00 - 15:00
P1 (Bauer/Weber) and P2 (Peteranderl/Becker)
May 29th, 13:00 - 15:00
P3 (Ziebuhr/Kracht) and P5 (Vadász/Samakovlis)
Sept 25th, 13:00 - 15:00
P6 (Morty/ Friebertshäuser/Ehrhardt), and P8 (Herold/Braun)
We are happy to announce that the KFO309 is funded by the DFG for a second funding period without any restriction for the next three years. We have one additional project now - welcome Natascha Sommer and Chrysanthi Skevaki who examnine the role of metabolic changes in T cell responses induced by viral infections that exacerbate COPD and emphysema in their P10 project.
KFO309 research on the cover of Pediatric Pulmonology
The KFO309 -(P6) -driven study on mouse strain susceptibility to hyperoxia, which was published in print form in the July issue of Pediatric Pulmonology, got both an Editorial, and the manuscript artwork also made the cover of the July issue of the journal.